

## DAFTAR PUSTAKA

- Ades F. Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. *J.Clin.Oncol.* 2014;32:2794–2803.
- Adhiatma D, Ali I, Ghoib H. Interleukin-6 serum levels in metastatic breast cancer and non-metastatic breast cancer. *International Journal of Health Sciences* 2022;6:3512-3520.
- Ahmad N, Ammar A, Storr SJ, Green AR, Rakha E, Ellis IO, et al. IL-6 and IL-10 are associated with good prognosis in early stage invasive breast cancer patients. *Cancer Immunol Immunother* 2018;67(4):537-549.
- Al Murri AM, Bartlett JM, Canney PA, Doughty JC, Wilson C, McMillan DC. Evaluation of an inflammation-based prognostic score (gps) in patients with metastatic breast cancer. *Br J Cancer* 2006;94(2):227–230.
- Al Murri AM, Wilson C, Lannigan A, Doughty JC, Angerson WJ, McArdle CS and McMillan DC: Evaluation of the relationship between the systemic inflammatory response and cancer-specific survival in patients with primary operable breast cancer. *Br J Cancer* 2007;96:891-895.
- Allin KH, Nordestgaard BG, Flyger H and Bojesen SE: Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: A cohort study. *Breast Cancer Res* 2011;13:R55.
- Asegaonkar S, Takalkar U, Kodlikeri P, Pagdhune A, Bonduliya V, Thorat A. Serum high sensitivity C-reactive protein in breast cancer patients. *International Journal of Research in Medical Sciences* 2014;2(4):1408–1411.
- Asegaonkar SB, Asegaonkar BN, Takalkar UV, Advani S, Thorat AP. C-reactive protein and breast cancer: new insights from old molecule. *International Journal of Breast Cancer* 2015;2015:145647.
- Black S, Kushner I, Samols D. C-reactive protein. *J. Biol. Chem.* 2004;279:48487–48490.
- Brady NJ, Chuntova P, Schwertfeger KL. Macrophages: regulators of the inflammatory microenvironment during mammary gland development and breast cancer. *Mediat. Inflamm.* 2016;2016:4549676.
- Bromberg J, Wang TC. Inflammation and cancer: IL-6 and STAT3 complete the link. *Cancer Cell.* 2009;15(2):79-80.
- Brooks GD, McLeod L, Alhayyani S, Miller A, Russell PA, Ferlin W, Jenkins BJ. IL6 Trans-signaling promotes KRAS-driven lung carcinogenesis. *Cancer Res.* 2016;76:866–876.
- Campbell IL, Erta M, Lim SL, Frausto R, May U, Rose-John S, Hidalgo J. Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain. *J. Neurosci.* 2014;34 (7):2503–2513.

- Cha-Molstad H, Young DP, Kushner I, and Samols D. The interaction of C-Rel with C/EBPbeta enhances C/EBPbeta binding to the C-reactive protein gene promoter. *Molecular Immunology* 2007;44(11):2933-2942.
- Chavey C, Bibeau F, Gourgou-Bourgade S, *et al.* Oestrogen receptor negative breast cancers exhibit high cytokine content. *Breast Cancer Res.* 2007;9(1):R15.
- Cheang MCU, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, *et al.* Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. *J. Natl. Cancer Inst.* 2009;101:736–750.
- Cho YA, Sung MK, Yeon JY, Ro J, Kim J. Prognostic role of interleukin-6, interleukin-8, and leptin levels according to breast cancer subtype. *Cancer Res Treat* 2013;45(3):210-219.
- Coe CL Love GD, Karasawa M, *et al.* 2011. Population differences in proinflammatory biology: Japanese have healthier profiles than Americans. *Brain Behav Immun.* 25(3):494-502.
- Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability. *Carcinogenesis* 2009;30:1073–1081.
- Danforth DN. The role of chronic inflammation in the development of breast cancer. *Cancers* 2021;13:3918.
- De Jager W, Bourcier K, Rijkers GT, *et al.* Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays. *BMC Immunology* 2009;10:52.
- Del Giudice M, Gangestad S.W. Rethinking IL-6 and CRP: why they are more than inflammatory biomarkers, and why it matters. *Brain Behav. Immun* 2018.
- Dhar SK, Lynn BC, Daosukho C, St Clair DK. Identification of nucleophosmin as an NF-κB co-activator for the induction of the human SOD2 gene. *J. Biol. Chem.* 2004;279(27):28209-28219.
- Du Clos TW, Mold C. C-reactive protein. *Immunol. Res.* 2004;30:261–277.
- Eisenhardt SU, Thiele JR, Bannasch H, Stark GB, Peter K. C-reactive protein: how conformational changes influence inflammatory properties. *Cell Cycle* 2009;8:3885–3892.
- Eklund CM. Proinflammatory cytokines in CRP baseline regulation. *Adv Clin Chem.* 2009;48:111-136.
- Eroles P, Bosch A, Pérez-Fidalgo JA, Lluch A. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. *Cancer Treat. Rev.* 2012;38:698–707.
- Fang J, Takahiro S, Hiroshi M. Therapeutic strategies by modulating oxygen stress in cancer and inflammation. *Adv Drug Deliv Rev.* 2009;61:290–302.
- Fang Y, Xu C, Wu P, Zhang LH, Li DW, Sun JH, Li WF and Liao ZS: Prognostic role of C-reactive protein in patients with nasopharyngeal carcinoma: A meta-analysis and literature review. *Medicine (Baltimore)* 2017;96:e8463.
- Ferlay J, Laversanne M, Ervik M, *et al.* *Global Cancer Observatory: Cancer Tomorrow*. International Agency for Research on Cancer: Lyon, France, 2020.

- Fontanini G, Campani D, Roncella M, *et al.* Expression of interleukin 6 (IL-6) correlates with oestrogen receptor in human breast carcinoma. *Br. J. Cancer* 1999;80(3-4):579-584.
- Frydenberg H, Thune I, Lofterød T, Mortensen ES, Eggen AE, Risberg T, Wist EA, Flote VG, Furberg AS, Wilsgaard T, *et al.* Pre-diagnostic high-sensitive C-reactive protein and breast cancer risk, recurrence, and survival. *Breast Cancer Res Treat* 2016;155:345-354.
- Fuster, JJ, Walsh, K. The good, the bad, and the ugly of interleukin-6signaling. *EMBO J.* 2014;33:1425–1427.
- Garbers C, Monhasery N, Aparicio-Siegmund S, Lokau J, Baran P, Nowell MA, Jones SA, Rose-John S, Scheller J. The interleukin-6 receptor Asp358Ala single nucleotide polymorphism rs2228145 confers increased proteolytic conversion rates by ADAM proteases. *Biochim Biophys Acta.* 2014;1842:1485–1494.
- Ghandadi M, Sahebkar A. Interleukin-6: a critical cytokine in cancer multidrug resistance. *Curr. Pharm.* 2016;22(5):518-526.
- Grivennikov S, Karin M. Autocrine IL-6 signaling: a key event in tumorigenesis? *Cancer Cell.* 2008;13(1):7-9.
- Guo L, Liu S, Zhang S, Chen Q, Zhang M, Quan P, Lu J, Sun X. C-reactive protein and risk of breast cancer: A systematic review and meta-analysis. *Sci. Rep.* 2015;5:10508.
- Guo Y, Xu F, Lu T, Duan Z, Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. *Cancer Treat Rev* 2012;38(7):904–910.
- Haddick PC, Larson JL, Rathore N, Bhargale TR, Phung QT, Srinivasan K, Farrer LA. A Common variant of IL-6R is associated with elevated IL-6 pathway activity in alzheimer’s disease brains. *J. Alzheimers Dis.* 2017;56(3):1037–1054.
- Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell* 2000;100(1):57-70.
- Hanna M, Dumas I, Orain M, Jacob S, Têtu B, Sanschagrin F, Bureau A, Poirier B, Diorio C. Association between expression of inflammatory markers in normal breast tissue and mammographic density among premenopausal and postmenopausal women. *Menopause.* 2017;24:524–535.
- Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principless of interleukin (IL)-6-type cytokine signalling and its regulation. *Biochem. J.* 2003;374(Pt 1):1-20.
- Hosokawa Y, Shindo S, Hosokawa I, Ozaki K, Matsuo T. IL-6 transsignaling enhances CCL20 production from IL-1b-stimulated human periodontal ligament cells. *Inflammation* 2014;37(2):381–386.
- Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LAG, Cronin KA. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. *J. Natl. Cancer Inst.* 2014;106:dju055.
- Hu H, Wei W, Yi X, Xin L, Liu Y. A retrospective analysis of clinical utility of AJCC 8<sup>th</sup> edition cancer staging system for breast cancer. *World J Oncol.* 2017;8(3):71-75.

- Hu Q, Gou Y, Sun C, Ding W, Xu K, Gu B, Xia G and Ding Q: The prognostic value of C-reactive protein in renal cell carcinoma: A systematic review and meta-analysis. *Urol Oncol* 2014;32(50):e1-50.e8.
- Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. *Nat. Immunol.* 2015;16(5):448-457.
- Kanu N, Cerone MA, Goh G, Zalmas P, Bartkova J, Dietzen M, McGranahan N, Rogers R, Law EK, Gromova I, *et al.* DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer. *Genome Biol.* 2016;17:185.
- Korkaya H, Kim GI, Davis A, *et al.* Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. *Mol. Cell* 2012;47(4):570-584.
- Korkaya H, Kim GI, Davis A, Malik F, Henry NL, Ithimakin S, *et al.* Activation of an IL6 Inflammatory Loop Mediates Trastuzumab Resistance in Her2+ Breast Cancer by Expanding the Cancer Stem Cell Population. *Mol Cell* 2012;47(4):570–584.
- Korkaya H, Kim GI, Davis A, Malik F, Henry NL, Ithimakin S, *et al.* Activation of an IL6 inflammatory loop mediates trastuzumab resistance in Her2+ breast cancer by expanding the cancer stem cell population. *Mol Cell* 2012;47(4):570–584.
- Kujawski M, Kortylewski M, Lee H, *et al.* STAT3 mediates myeloid cell-dependent tumor angiogenesis in mice. *J. Clin. Invest.* 2008;118(10):3367-3377.
- Kumari N, Dwarakanath BS, Das A, Bhatt AN. Role of interleukin-6 in cancer progression and therapeutic resistance. *Tumour Biol.* 2016;37(9):11553-11572.
- Kuong KJ, A Loeb L. APOBEC3B mutagenesis in cancer. *Nat. Genet.* 2013;45:964–965.
- Kwa M, Makris A, Esteva FJ. Clinical utility of gene-expression signatures in early stage breast cancer. *Nat Rev Clin Oncol* 2017;14:595-610.
- Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. *Nat. Rev. Mol. Cell Biol.* 2014;15(3):178-196.
- Laskin DL, Sunil VR, Gardner CR, Laskin JD. Macrophages and tissue injury: agents of defense or destruction? *Annu. Rev. Pharm. Toxicol.* 2011;51:267–288.
- Lin S, Gan Z, Han K, Yao Y, Min D. Interleukin-6 as a prognostic marker for breast cancer: a meta-analysis. *Tumori* 2015;101(5):535-541.
- Liu X, Ma Y, Yang W, Wu X, Jiang L, Chen X. Identification of therapeutic targets for breast cancer using biological informatics methods. *Mol Med Rep* 2015;12(2):1789–1795.
- Liu ZQ, Chu L, Fang JM, Zhang X, Zhao HX, Chen YJ and Xu Q: Prognostic role of C-reactive protein in prostate cancer: A systematic review and meta-analysis. *Asian J Androl* 2014;16:467-471.
- Lo CW, Chen MW, Hsiao M, Wang S, Chen CA, Hsiao SM, Wei LH. IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. *Cancer Res.* 2011;71(2):424–434.

- Lukasiewicz S, Czezelewski M, Forma A, Baj J, Sitarz R, Stanislawek A. Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review. *Cancers*. 2021;13:4287.
- Luo Y, Fu SJ, She DL, Xiong HU and Yang LI: Preoperative C-reactive protein as a prognostic predictor for upper tract urothelial carcinoma: A systematic review and meta-analysis. *Mol Clin Oncol* 2015;3:924-928.
- Ma S, Guo C, Sun C, Han T, Zhang H, Qu G, Jiang Y, Zhou Q, Sun Y. Aspirin use and risk of breast cancer: a meta-analysis of observational studies from 1989 to 2019. *Clin. Breast Cancer*. 2021.
- Madden KS, Szpunar MJ, Brown EB. Beta-adrenergic receptors (beta-AR) regulate VEGF and IL-6 production by divergent pathways in high beta-AR-expressing breast cancer cell lines. *Breast Cancer Res. Treat.* 2011;130(3):747-758.
- Masjedi A, Hashemi V, Hojjat-Farsangi M, *et al.* The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer. *Biomedicine & Pharmacotherapy* 2018;108:1415-1424.
- Mihlan M, Blom AM, Kupreishvili K, Lauer N, Stelzner K, Bergström F, Zipfel PF. Monomeric C-reactive protein modulates classic complement activation on necrotic cells. *FASEB J.* 2011;25:4198–4210.
- Mohammed ZM, Going JJ, Edwards J, Elsberger B, Doughty JC, McMillan DC. The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer. *Br. J. Cancer*. 2012;107:864–873.
- Moon A, Kim ES, Bae M, *et al.* Inflammatory lipid sphingosine-1-phosphate upregulates C-reactive protein via C/EBP $\beta$  and potentiates breast cancer progression. *The FASEB Journal* 2015; 29(Suppl 1):728.12.
- Multhoff G, Molls M, Radons J. Chronic inflammation in cancer development. *Front. Immunol.* 2012;2:98.
- Nagasaki T, Hara M, Nakanishi H, *et al.* Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction. *Br. J. Cancer* 2014;110(2):469-478.
- Panigrahy D, Gartung A, Yang J, Yang H, Gilligan MM, Sulciner ML, Bhasin SS, Bielenberg DR, Chang J, Schmidt BA, *et al.* Preoperative stimulation of resolution and inflammation blockade eradicates micrometastases. *J. Clin. Investig.* 2019;129:2964–2979.
- Pasanisi P, Venturelli E, Morelli D, Fontana L, Secreto G, Berrino F. Serum insulin-like growth factor-I and platelet-derived growth factor as biomarkers of breast cancer prognosis. *Cancer Epidemiol Biomarkers Prev* 2008;17(7):1719–1722.
- Perou C, Sørlie T, Eisen M, VanDeRijn M, Jeffrey S, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, *et al.* Molecular portraits of human breast tumours. *Nat. Cell Biol.* 2000;406:747–752.
- Porter P. Westernizing Women's Risks? Breast Cancer in Lower-Income Countries. *N. Engl. J. Med.* 2008;358:213–216.



- Prat A, Carey LA, Adamo B, Vidal M, Tabernero J, Cortes J, Parker JS, Perou C., Baselga J. Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. *J. Natl. Cancer Inst.* 2014;106:dju152.
- Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. *Mol. Oncol.* 2001;5:5–23.
- Qiu SQ, Waaijer SJH, Zwager MC, DeVries EGE, VanDerVegt B, Schröder CP. Tumor-associated macrophages in breast cancer: innocent bystander or important player? *Cancer Treat. Rev.* 2018;70:178–189.
- Raj-Kumar PK, Liu J, Hooke JA, Kovatich AJ, Kvecher L, Shriver CD, Hu H. PCA-PAM50 improves consistency between breast cancer intrinsic and clinical subtyping reclassifying a subset of luminal A tumors as luminal B. *Sci. Rep.* 2019;9:7956.
- Ravishankaran P and Karunanithi R: Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients. *World J Surg Oncol* 2011;9:18.
- Rose-John S, Winthrop K, Calabrese L. The role of IL-6 in host defense against infections: immunobiology and clinical implications. *Nat. Rev. Rheumatol.* 2007;13:399–409.
- Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang, ES, Coussens, LM. Leukocyte composition of human breast cancer. *Proc. Natl. Acad. Sci. USA.* 2012;109:2796–2801.
- Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E, *et al.* Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. *Int J Cancer* 2003;103(5):642–646.
- Sansone P, Storci G, Tavolari S, *et al.* IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. *J. Clin. Invest.* 2007;117(12):3988–4002.
- Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro-and anti-inflammatory properties of the cytokine interleukin-6. *BBA* 2011;1813:878–888.
- Schmit X, Vincent JL. The time course of blood C-reactive protein concentrations in relation to the response to initial antimicrobial therapy in patients with sepsis. *Infection* 2008;36:213–219.
- Shah R, Rosso K, Nathanson SD. Pathogenesis, prevention, diagnosis, and treatment of breast cancer. *World J Clin Oncol* 2014;5(3):283–298.
- Sharma R. Breast cancer incidence, mortality and mortality-to-incidence ratio (MIR) are associated with human development 1990–2016: Evidence from Global Burden of Disease Study 2016. *Breast Cancer.* 2019;26:428–445.
- Shibayama O, Yoshiuchi K, Inagaki M, *et al.* Association between adjuvant regional radiotherapy and cognitive function in breast cancer patients treated with conservation therapy. *Cancer Med.* 2014;3(3):702–709.
- Shimura T, Shibata M, Gonda K, *et al.* Prognostic impact of interleukin-6 and C-reactive protein on patients with breast cancer. *Oncology Letters* 2019;17:5139–5146.

- Sicking I, Edlund K, Wesbuer E, Weyer V, Battista MJ, Lebrecht A, Solbach C, Grinberg M, Lotz J, Hoffmann G, *et al.* Prognostic influence of pre-operative C-reactive protein in node-negative breast cancer patients. *PLoS One* 2014;9:e111306.
- Singh A, Purohit A, Ghilchik MW, *et al.* The regulation of aromatase activity in breast fibroblasts: the role of interleukin-6 and prostaglandin E2. *Endocr. Relat. Cancer* 1999;6(2):139-147.
- Sørli, T. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc. Natl. Acad. Sci. USA*. 2001;98:10869–10874.
- Stevens L, Pathak S, Nunes QM, Pandanaboyana S, Macutkiewicz C, Smart N and Smith AM: Prognostic significance of pre-operative C-reactive protein and the neutrophil-lymphocyte ratio in resectable pancreatic cancer: A systematic review. *HPB (Oxford)* 2015;17: 285-291.
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, *et al.* Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2021;71(3):209-249.
- Szabo-Fresnais N, Lefebvre F, Germain A, Fischmeister R, Pomérance M. A new regulation of IL-6 production in adult cardiomyocytes by  $\beta$ -adrenergic and IL-1b receptors and induction of cellular hypertrophy by IL-6 transsignalling. *Cell. Signal*. 2010;22 (7);1143–1152.
- Tavassoli FA. *Pathology and genetics of tumours of the breast and female genital organs*. World Health Organization Classification of Tumours: Lyon, France, 2003.
- Thiele JR, Habersberger J, Braig D, Schmidt Y, Goerendt K, Maurer V, Kolodgie F. The dissociation of pentameric to monomeric C-reactive protein localizes and aggravates inflammation: In vivo proof of a powerful proinflammatory mechanism and a new anti-inflammatory strategy. *Circulation* 2014;130:35–50.
- Tian J, Chen X, Fu S, Zhang R, Pan L, Cao Y, *et al.* Bazedoxifene Is a Novel IL-6/Gp130 Inhibitor for Treating Triple-Negative Breast Cancer. *Breast Cancer Res Treat* 2019;75(3):553–566.
- Tibau A, Ennis M and Goodwin PJ: Post-surgical highly sensitive C-reactive protein and prognosis in early-stage breast cancer. *Breast Cancer Res Treat* 2013;141:485-493.
- Trial J, Potempa LA, Entman ML. The role of C-reactive protein in innate and acquired inflammation: new perspectives. *Inflammation Cell Signaling* 2016;3:e1409.
- Tripsianis G, Papadopoulou E, Anagnostopoulos K, *et al.* Coexpression of IL-6 and TNF- $\alpha$ : prognostic significance on breast cancer outcome. *Neoplasma* 2014;61(2):205-212.
- Vakkila J and Lotze MT. Inflammation and necrosis promote tumour progression and metastasis. *Nature Reviews Cancer* 2004;4:71-78.

- Vakkila J, Lotze MT. Inflammation and necrosis promote tumour progression and metastasis. *Nature Reviews Cancer* 2004;4:71–78.
- Velásquez IM, Golabkesh Z, Källberg H, Leander K, de Faire U, Gigante B. Circulating levels of interleukin 6 soluble receptor and its natural antagonist, sgp130, and the risk of myocardial infarction. *Atherosclerosis* 2015;240(2), 477–481.
- Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. *JAMA*. 1999;282:2131–2135.
- Wang CS and Sun CF. C-reactive protein and malignancy: clinico-pathological association and therapeutic implication. *Chang Gung Medical Journal* 2009;32(5):471-482.
- Wang D, Xu J, Liu B, He X, Zhou L, Hu X, *et al.* Il6 Blockade Potentiates the Anti-Tumor Effects of Gamma-Secretase Inhibitors in Notch3-Expressing Breast Cancer. *Cell Death Differ* 2018;25(2):330–409.
- Wang M, Chen S, He X, Yuan Y, Wei X. Targeting inflammation as cancer therapy. *Journal of Hematology & Oncology* 2024;17:13.
- Wilopo SA (ed.). 2021. *Sampling dan Besar Sampel*. Yogyakarta: Pusat Kesehatan Reproduksi Fakultas Kedokteran Universitas Gadjah Mada.
- Woo HD, Kim K and Kim J: Association between preoperative C-reactive protein level and colorectal cancer survival: A meta-analysis. *Cancer Causes Control* 2015;26:1661-1670.
- Worster A, Innes G, Abu-Laban RB. Diagnostic testing: an emergency medicine perspective. *Can J Emerg Med* 2002;4(5):348-354.
- Xu Y, Fang F, Dhar SK, *et al.* The role of a single-stranded nucleotide loop in transcriptional regulation of the human *sod2* gene. *J. Biol. Chem.* 2007;282(22):15981-15994.
- Yaghjyan L, Colditz G, Rosner B, Tamimi RM. Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to the time since the mammogram. *Cancer Epidemiol. Biomark. Prev.* 2013;22:1110–1117.
- Zhang GJ, Adachi I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. *Anticancer Res* 1999;19(2B):1427–32.
- Zheng Z, Zhou L, Gao S, Yang Z, Yao J and Zheng S. Prognostic role of C-reactive protein in hepatocellular carcinoma: A systematic review and meta-analysis. *Int J Med Sci* 2013;10:653-664.
- Zubor P, Hatok J, Moricova P, Kapustova I, Kajo K, Mendelova A, *et al.* Gene expression profiling of histologically normal breast tissue in females with human epidermal growth factor receptor 2 positive breast cancer. *Mol Med Rep* 2015;11(2):1421–1427.